DNA Q3 2024 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$89M+60.6% YoY

Gross Profit

$79M88.8% margin

Operating Income

-$55M-62.0% margin

Net Income

-$56M-63.3% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

+58.4%

Cash Flow

Operating Cash Flow

-$104M

Free Cash Flow

-$119M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$683M

Stockholders' Equity

$798M

Cash & Equivalents

$616M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$89M	$55M	+60.6%
Gross Profit	$79M	$49M	+63.0%
Operating Income	-$55M	-$286M	+80.7%
Net Income	-$56M	-$303M	+81.4%

Revenue Segments

Service

$14M100%